Adams CM. Spermine oxidase maintains basal skeletal muscle gene expression and fiber size and is strongly repressed by conditions that cause skeletal muscle atrophy.
life, falls, fractures, delayed recovery from acute illness, loss of independent living, and increased mortality (4, 18, 25, 46) . Although the clinical implications of muscle atrophy are broad, a pharmacological therapy does not exist. Furthermore, therapeutic advances are hindered by the fact that muscle atrophy remains poorly understood at the molecular level.
Some insight into the molecular mechanisms of muscle atrophy has been gained through investigations of mRNA expression changes that occur in atrophying skeletal muscle. Through a complex network of signaling pathways, primary causes of muscle atrophy generate new patterns of mRNA expression in skeletal muscle (1, 5, 16, 19, 20, 22, 24, 30, 39, 44, 48, 49) . These patterns, or signatures, consist of mRNAs that are expressed at relatively low levels in healthy skeletal muscle but are significantly increased by conditions that cause muscle atrophy, and also mRNAs that are expressed at relatively high levels in healthy skeletal muscle, but are significantly decreased by conditions that cause muscle atrophy. Because mRNA expression signatures of muscle atrophy are highly specific and crucial for atrophy, they can be used to identify pharmacological approaches that attenuate muscle atrophy (13, 24) , as well as proteins that play key roles in the pathogenesis of muscle atrophy. For example, investigations focused on certain mRNAs that are strongly induced in atrophying muscle have identified proteins that actively promote muscle atrophy, including key transcriptional regulators and proteins involved in ubiquitin-mediated proteolysis and autophagy (5, 6, 14, 15, 17, 21, 23, 32, 33, 35) . Conversely, mRNAs that are strongly repressed in atrophic muscle encode proteins that promote mitochondrial function and other cellular processes that help to maintain skeletal muscle mass but are impaired during muscle atrophy (10, 11, 27, 40, 50) .
Despite these advances, the vast majority of skeletal muscle mRNAs whose levels are significantly altered during muscle atrophy remain unstudied. On this basis, we hypothesized that critical regulators of skeletal muscle mass remain to be discovered. Thus, in the current study, we sought to identify a positive regulator of muscle mass and a previously unrecognized mechanism of muscle atrophy by identifying and investigating an mRNA transcript that is strongly and specifically repressed in atrophic skeletal muscle.
MATERIALS AND METHODS

Chemicals and antibodies.
We obtained HPLC-grade spermine, spermidine, methanol, and acetonitrile from Sigma; N,N=-bis(3-aminopropyl)-1,4-butane-d 20-diamine (deuterated spermine) from SDS-PAGE and then transferred to Hybond-C extra nitrocellulose membranes (Millipore). Immunoblots were performed for 16 h at 4°C using a 1:2,000 dilution of anti-spermine oxidase antibody (used to detect endogenous and overexpressed spermine oxidase), a 1:1,000 dilution of antip21 antibody (used to detect endogenous and overexpressed p21 in Fig.  6 ), a 1:3,000 anti-FLAG antibody (used to detect overexpressed p21 in Fig. 7 ), a 1:1,000 dilution of anti-mitofusin-2 antibody (used to detect endogenous mitofusin-2), or a 1:500 dilution of anti-myogenin antibody (used to detect endogenous myogenin). Membranes were stained with Ponceau S to ensure equal loading.
Measurement of skeletal muscle spermine and spermidine levels. Stock solutions of spermine and spermidine were prepared by dissolving spermine and spermidine in a water-methanol (80:20 vol/vol) solution at a concentration of 1 mg/ml. Working standards were prepared by combining 10 l of each stock solution with 980 l of water-methanol (to form a working standard containing 10 g/ml spermine and 10 g/ml spermidine), followed by serial dilution of this working standard in water-methanol (to form less concentrated working standards containing 1 g/ml spermine and spermidine and 100 ng/ml spermine and spermidine). The internal standard was prepared by dissolving deuterated spermine in water-methanol at a concentration of 10 g/ml. All solutions were stored at 4°C and brought to 21°C before use.
To generate blank samples, calibration standards, and positive controls, 400 mg of skeletal muscle from control mice was homogenized in 3.2 ml of ultrapure water, and then centrifuged at 10,000 rpm for 5 min. Calibration standards and positive controls were prepared by spiking 200 l of homogenate with working standards at 10, 50, 500, 1,000, and 2,000 ng/ml of spermine and spermidine (calibration standards) and 100 and 800 ng/ml (positive controls). We then added 10 l of internal standard and 600 l of ammonium hydroxide (1% wt/vol water) to each blank, calibration standard, and positive control. To prepare experimental samples, mouse skeletal muscles were harvested under conditions described in the figure legends, weighed, homogenized at high speed for 15 s in 300 l of ultrapure water and centrifuged at 10,000 rpm for 5 min. We then transferred 200 l of homogenate to a fresh vial and added 10 l of internal standard and 600 l of 1% ammonium hydroxide. Agilent BondElut-PSA solid-phase extraction cartridges (no. 12102015) were used for sample extraction on a Cerex SPE processor (Varian). Cartridges were conditioned with methanol and equilibrated with 1% ammonium hydroxide in water. Samples were then loaded into cartridges using nitrogen flow at a rate of 1 ml/min. The cartridges were rinsed with 1% ammonium hydroxide in water and the analytes eluted with 1% ammonium hydroxide in methanol. Eluates were dried under flowing nitrogen at 35°C for 35 min. The residue was reconstituted with 320 l of 0.1% formic acid and 0.02% HFBA in ultrapure water (Mobile A) and 80 l of 0.1% formic acid and 0.02% HFBA in acetonitrile (Mobile B).
Liquid chromatography separation was performed on a Shimadzu 2010A high-performance liquid chromatography-mass spectrometry (HPLC-MS) system using electrospray ionization mode and operating LC-MS Solution software (version 2.04H3, Shimadzu). A Poroshell 120 SB-C18 analytic column (Agilent) protected by a high-pressure column prefilter and a Phenomenex C18 ultra HPLC security guard column (no. AJ0-8768) was held at 40°C. Chromatographic separation was done by gradient elution using aqueous Mobile A and organic Mobile B. The gradient elution started with 10% Mobile B, which increased to 50% at 6 min; the column was then rinsed at 90% Mobile B for 1 min, and the system was equilibrated back to 10% Mobile B for 4 min. The analytes were eluted at the retention times of 3.9 min (spermidine) and 4.6 min (spermine and deuterated spermine), using a 0.25 ml/min flow rate and a 5-l injection volume. The mass spectrometer was tuned using a polyethylene glycol solution following the manufacturer's protocol. The electrospray source was operated in positive mode; the CDL and heat block were heated to 250°C, nitrogen flow rate was 1.5 l/min, and detector voltage was 1.6 kV. Nitrogen gas at 14.5 psi was flowing in the ionization chamber. The scan interval was 0. Plasmids. p-Spermine Oxidase encodes the -isoform of spermine oxidase with three copies of the FLAG epitope tag at the NH 2 terminus, under control of the cytomegalovirus (CMV) promoter. To generate p-Spermine Oxidase, we obtained a full-length mouse spermine oxidase cDNA from Genscript (Clone ID F16960), and then subcloned the cDNA into the p3XFLAG-CMV10 vector (Sigma). p-Spermine Oxidase (H82E/T558Y) encodes the -isoform of spermine oxidase with two point mutations (H82E and T558Y) that disrupt spermine oxidase activity (47) and was generated by site-directed mutagenesis of p-Spermine Oxidase. p-eGFP encodes enhanced green fluorescent protein (eGFP) under control of the CMV promoter. p-miR-Control was described previously (14) and encodes emerald green fluorescent protein (EmGFP) and a nontargeting pre-miRNA under bicistronic control of the CMV promoter in the pcDNA6.2GW/ EmGFP-miR plasmid (Invitrogen). p-miR-Spermine Oxidase #1 and p-miR-Spermine Oxidase #2 encode EmGFP and artificial pre-miRNAs targeting mouse spermine oxidase under bicistronic control of the CMV promoter and were generated by ligating Mmi528584 and Mmi528586 oligonucleotide duplexes (Invitrogen), respectively, into the pcDNA6.2GW/EmGFP-miR plasmid. p-p21 has been described previously (17) and encodes mouse p21 with three copies of the FLAG epitope tag at the NH 2 terminus, under control of the CMV promoter. p-miR-p21 was described previously (as "p-miR-p21 #1" in Ref. 17) and encodes EmGFP and an artificial pre-miRNA targeting mouse p21 under bicistronic control of the CMV promoter in the pcDNA6.2GW/EmGFP-miR plasmid.
Histological analysis of mouse skeletal muscle. Harvested muscles were immediately fixed in 4% (wt/vol) paraformaldehyde for 16 h Fig. 1 . Limb immobilization decreases spermine oxidase in skeletal muscle. A: to identify skeletal muscle mRNAs that are most reduced by limb immobilization, we examined data from a previous study (17) . In that study, 2-mo-old C57BL/6 mice were subjected to unilateral hindlimb immobilization for 3 days, and mRNA from bilateral tibialis anterior (TA) muscles (mobile and immobile) was analyzed with Illumina MouseRef-8 v. 2.0 BeadChip arrays (n ϭ 4 arrays per condition). In each mouse, probe signals from the immobilized TA were normalized to probe signals from the contralateral (mobile) TA, and P values were determined with paired t-tests. Statistical significance was arbitrarily defined as P Յ 0.05. The figure shows the 15 annotated probe signals that were most reduced by immobilization. B-D: 2-mo-old C57BL/6 mice were subjected to unilateral hindlimb immobilization for 3 days, and bilateral TA muscles were harvested for analysis. B: qPCR analysis of spermine oxidase mRNA; n ϭ 6 muscles per condition. C: immunoblot analysis of spermine oxidase. Left: representative immunoblot. Right: quantification; n ϭ 4 muscles per condition. Membranes were stained with Ponceau S to confirm equal loading. D: quantification of spermine by HPLC-MS; n ϭ 8 muscles per condition. B-D: data are means Ϯ SE; *P Յ 0.05. at 4°C and then incubated in 30% sucrose (wt/vol) for 24 h. The muscles were then embedded in Tissue Freezing Medium (Triangle Biomedical Sciences), and a Microm HM 505E cryostat was used to prepare 10-m sections from the muscle midbelly. Sections were washed with PBS three times, mounted with Vectashield (Vector Laboratories), and then imaged on an Olympus IX-71 microscope equipped with a DP-70 camera. Images were analyzed with ImageJ, and transfected fibers were defined as fibers with a mean fluorescence of Ն25 arbitrary units above background, as previously described (15) . The diameters of Ն200 muscle fibers per muscle were measured using the lesser diameter method, as recommended elsewhere (12) . + statistical significance was defined as P Յ 0.05 and FDR Յ 0.25, as previously described (34) .
RESULTS
Conditions that cause skeletal muscle atrophy strongly repress spermine oxidase expression in skeletal muscle. Our overall goal in this study was to identify a skeletal muscle protein whose function helps to maintain muscle mass but is inhibited by conditions that cause muscle atrophy. We reasoned that such a protein 1) might be reduced in atrophic skeletal muscle, 2) might begin to be reduced as muscle atrophy begins to occur, and 3) might be decreased via a reduction in the mRNA that encodes this protein.
To begin to test this hypothesis, we used unbiased, genome-wide mRNA expression arrays to search for mRNAs that are strongly repressed in the mouse TA muscle by a short period of limb immobilization (3 days). Importantly, 3 days of limb immobilization is sufficient to induce a small but significant amount of skeletal muscle atrophy (17) . Our mRNA expression arrays were Illumina Mouse Ref-8 v2.0 BeadChip arrays, which contain 25,697 probes directed against 17,192 unique mRNAs, including five probes directed against spermine oxidase mRNA. Interestingly, three days of limb immobilization strongly repressed the signals from all five spermine oxidase probes, which represented the 1st, 2nd, 5th, 12th, and 15th most repressed annotated probe signals from immobilized TA muscle (Fig. 1A) . We performed qPCR analysis to confirm that 3 days of limb immobilization significantly reduced the amount of spermine oxidase mRNA in TA muscle (Fig. 1B) .
Spermine oxidase is a FAD-dependent oxidase that specifically catabolizes spermine into spermidine, 3-aminopropanal, and H 2 O 2 (8, 9) . Its role in the control of skeletal muscle mass was unknown. To determine whether limb immobilization also reduced spermine oxidase protein, we performed immunoblot analysis. Under basal conditions, TA muscle contained a high level of spermine oxidase protein (Fig. 1C) , and the molecular mass of this protein (65 kDa) was consistent with it being the longest () isoform of spermine oxidase, which is catalytically active (9) . As predicted by its effects on spermine oxidase mRNA, three days of limb immobilization significantly reduced the level of spermine oxidase protein in TA muscle (Fig. 1C) . Moreover, 3 days of limb immobilization significantly increased the level of spermine in TA muscle, consistent with reduced spermine oxidase activity (Fig. 1D) . Interestingly, muscle immobilization did not alter the level of spermidine (levels were 18.9 Ϯ 2.3 mg spermidine/g mobile muscle and 18.5 Ϯ 1.1 mg spermidine/g immobile muscle, P ϭ 0.96), suggesting that other enzymes or transporters are able to maintain the level of spermidine when spermine oxidase activity is reduced.
The finding that muscle immobilization reduced spermine oxidase expression led us to investigate whether similar changes might also occur during other conditions that cause muscle atrophy, such as 24 h of fasting (15), 7 days of muscle denervation (14) , and 22 mo of aging (50) . Like muscle immobilization, fasting reduced spermine oxidase mRNA and spermine oxidase protein in skeletal muscle (Fig. 2, A and B) , and it increased the level of spermine in skeletal muscle (Fig. 2C) . Similarly, muscle denervation reduced spermine oxidase mRNA and spermine oxidase protein (Fig. 2, D and E), and it increased the level of spermine in skeletal muscle (Fig. 2F) . Furthermore, 22-moold mice, which exhibit age-related muscle atrophy (50), contained reduced levels of spermine oxidase mRNA and spermine oxidase protein and an increased amount of spermine in their skeletal muscles relative to 6-mo-old control mice (Figs. 2, G-I). For reasons that are not clear to us at this point, the basal level of spermine varied somewhat from experiment to experiment (see Figs. 1D, and 2, C, F, and I). However, the relative level of spermine was consistently higher during conditions that reduced spermine oxidase expression and cause muscle atrophy (see Figs. 1D and 2, C, F, and I). Thus, during muscle immobilization, fasting, muscle denervation, and aging, skeletal muscle atrophy is associated with a significant reduction in spermine oxidase and a relative increase in the level of spermine.
Spermine oxidase has a positive effect on muscle fiber size that protects against muscle fiber atrophy. Because spermine oxidase was reduced by conditions that cause muscle atrophy, we hypothesized that spermine oxidase might have a positive effect on skeletal muscle fiber size, which decreases during muscle atrophy. To test this hypothesis, we used in vivo electroporation [a method that transfects terminally differentiated skeletal muscle fibers but not satellite cells or connective tissue cells (42) ] to transfect mouse TA muscle fibers with a plasmid encoding spermine oxidase. In each mouse, the contralateral TA muscle was transfected with an empty plasmid and served as an intrasubject control. As expected, transfection of spermine oxidase plasmid increased spermine oxidase mRNA and spermine oxidase protein (Fig. 3, A and B) , and it reduced the level of spermine in skeletal muscle (Fig. 3C) . Importantly, increased expression of spermine oxidase led to an increase in muscle fiber size (Figs. 3, D and E) . As an additional control, we transfected skeletal muscle fibers with plasmid encoding spermine oxidase (H82E/T558Y), a spermine oxidase construct that contains two point mutations that abolish spermine oxidase activity (47) . Although spermine oxidase (H82E/T558Y) was highly expressed (Fig. 3, F and G) , it did not decrease spermine levels (Fig. 3H) or increase muscle fiber size (Fig. 3, I and J) , suggesting that catalytic activity may be required for spermine oxidase's positive effect on muscle fiber size. Interestingly, spermine oxidase (H82E/T558Y) appeared to have a dominant negative effect, as it increased spermine and decreased muscle fiber size (Figs. 3, H-J) .
The finding that spermine oxidase (H82E/T558Y) reduced muscle fiber size, coupled with the finding that spermine oxidase expression is reduced during muscle atrophy, suggested that reduced spermine oxidase activity might be sufficient to induce muscle fiber atrophy. To test this hypothesis, we used RNA interference to reduce the level of spermine oxidase in skeletal muscle fibers. To this end, we generated two artificial microRNA (miR) constructs (miR-Spermine Oxidase #1 and miR-Spermine Oxidase #2) that target distinct regions of the spermine oxidase mRNA and specifically reduce spermine oxidase protein (Fig. 4A) . We then transfected skeletal muscle fibers in vivo with plasmids encoding either miR-Spermine Oxidase #1, miR-Spermine Oxidase #2, or a nontargeting control miRNA (miR-Control). We found that knockdown of spermine oxidase with either miR-Spermine Oxidase construct markedly reduced muscle fiber size (Fig. 4, B and C) . Taken together, these data indicate that reduced spermine oxidase expression (as seen during immobilization, fasting, denervation, and aging) is sufficient to induce muscle fiber atrophy. To determine whether forced expression of spermine oxidase might increase the size of atrophic muscle fibers, we transfected skeletal muscle fibers with plasmid encoding wild-type spermine oxidase and then induced muscle atrophy via limb immobilization (Fig. 5A), fasting (Fig. 5B) , or muscle denervation (Fig. 5C ). In each of these atrophy conditions, forced expression of spermine oxidase increased muscle fiber size, suggesting that decreased spermine oxidase expression is both necessary and sufficient for muscle fiber atrophy. p21 mediates the repression of spermine oxidase during muscle atrophy. On the basis of our findings that decreased spermine oxidase expression promotes muscle fiber atrophy, and that the reduction in spermine oxidase expression during muscle atrophy can be explained, at least in part, by a reduction in spermine oxidase mRNA, we investigated whether spermine oxidase mRNA might be reduced by a protein that is known to actively promote muscle atrophy, p21. In sharp contrast to spermine oxidase, p21 is expressed at low levels in healthy skeletal muscle, and it is highly induced by conditions that decrease spermine oxidase expression and induce muscle atrophy [e.g., aging, denervation, fasting, hindlimb unloading, amyotrophic lateral sclerosis (ALS), and critical illness (1, 5, 15, 16, 20, 22, 26, 30, 44, 48, 49) ]. Furthermore, increased p21 expression is sufficient to induce muscle fiber atrophy, and it is required for muscle atrophy induced by 3 days of muscle immobilization (17) . These considerations led us to hypothesize that p21 might be responsible for repressing spermine oxidase mRNA during muscle atrophy.
To begin to test this hypothesis, we transfected skeletal muscle fibers with a plasmid encoding p21, which is sufficient to induce muscle fiber atrophy (17) . We then used Illumina Mouse Ref -8 v2 .0 BeadChip arrays to analyze the effect of p21 on skeletal muscle mRNA levels. Remarkably, p21 overexpression strongly repressed the signals from all five spermine oxidase probes, which represented the 1st, 2nd, 3rd, 4th, and 9th most repressed annotated probe signals from muscles overexpressing p21 (of Ͼ25,000 measured probe signals) (Fig. 6A) . qPCR analysis confirmed that p21 overexpression significantly reduced the level of spermine oxidase mRNA in skeletal muscle (Fig. 6B) . Consistent with its effect on spermine oxidase mRNA, p21 also reduced the level of spermine oxidase protein (Fig. 6C) and increased the level of spermine in skeletal muscle (Fig. 6D) . These data indicate that increased p21 expression is sufficient to reduce spermine oxidase expression and activity in skeletal muscle.
To determine whether p21 is required for the reduction of spermine oxidase expression during muscle atrophy, we transfected skeletal muscle fibers with plasmids encoding either miRControl or miR-p21, an artificial microRNA that specifically reduces p21 expression in skeletal muscle and inhibits muscle fiber atrophy induced by limb immobilization (17) . We then induced endogenous p21 expression by immobilizing the transfected skeletal muscles for 3 days. As expected, miR-p21 decreased p21 mRNA and p21 protein in immobilized muscle (Fig.  6, E and F) . Importantly, this reduction in p21 was accompanied by an increase in spermine oxidase mRNA and spermine oxidase protein (Fig. 6 , E and F) and a reduction in the level of spermine in skeletal muscle (Fig. 6G) . Taken together, these data indicate that p21 is at least partially required for the repression of spermine oxidase during immobilization-induced muscle atrophy.
To test whether forced expression of spermine oxidase might reduce p21-mediated muscle fiber atrophy, we overexpressed p21 in the absence and presence of plasmid encoding spermine oxidase (Fig. 7A) . We found that spermine oxidase signifi- cantly increased muscle fiber size in the presence of p21 (Figs.  7, B-D) . Since p21 induces muscle fiber atrophy (17) , these data suggest that the repression of spermine oxidase is an important downstream event in p21-mediated muscle atrophy. sidered the fact that spermine is a major cationic component of cells, capable of binding to acidic sites on proteins and nucleic acids and influencing cellular gene expression (37) . From this perspective, we hypothesized that spermine oxidase might influence muscle fiber gene expression in a way that maintains muscle fiber size and prevents muscle fiber atrophy. Furthermore, because spermine oxidase is reduced during muscle atrophy (at least in part due to the actions of p21), we hypothesized that important effects of spermine oxidase would be opposed by a bona fide atrophy stimulus (muscle immobilization) and by p21 overexpression. To begin to test this hypothesis, we transfected skeletal muscle fibers with plasmid encoding wild-type spermine oxidase and then determined effects of spermine oxidase on skeletal muscle mRNA levels with Illumina Mouse Ref-8 v2.0 BeadChip arrays. We then compared the effects of spermine oxidase overexpression to the effects of muscle immobilization (Fig. 1A) and the effects of p21 overexpression (Fig. 6A) .
To identify mRNA transcripts that might contribute to the positive effects of spermine oxidase on muscle fiber size, we searched for skeletal muscle mRNAs that were 1) increased by spermine oxidase and decreased by muscle immobilization and p21, or 2) decreased by spermine oxidase and increased by muscle immobilization and p21. All together, we identified 21 mRNAs (including spermine oxidase itself) that were increased by spermine oxidase and decreased by immobilization and p21, and 14 mRNAs that were decreased by spermine oxidase and increased by immobilization and p21 (Fig. 8A) . Not surprisingly, most of these mRNAs encode proteins that have not been studied in the context of skeletal muscle atrophy. However, it was interesting that spermine oxidase increased (and immobilization and p21 decreased) several mRNAs involved in mitochondrial structure and function [e.g., the mRNA encoding mitofusin-2, which is required for maintenance of skeletal muscle mass (10); Fig. 8A ]. It was also notable that spermine oxidase decreased (and immobilization and p21 increased) mRNAs encoding the myogenic regulatory factor myogenin (Fig. 8A) , which promotes muscle atrophy (35) . We used qPCR to confirm that mitofusin-2 mRNA was decreased by immobilization and p21 and increased by spermine oxidase, and to confirm that myogenin mRNA was increased by immobilization and p21 and decreased by spermine oxidase (Fig. 8B) . As predicted by these changes in mRNA levels, immunoblot analyses showed that spermine oxidase increased mitofusin-2 protein (Fig. 8C ) and decreased myogenin protein (Fig. 8D) .
To identify cellular processes that are induced or repressed by spermine oxidase and regulated in the opposite direction by immobilization and p21, we performed gene set enrichment analysis (34) . By this method, we identified 10 gene sets that were induced by spermine oxidase and repressed by immobilization and p21 (Fig. 9) ; the majority of these gene sets represented cellular processes that contribute to mitochondrial biogenesis and function, which are known to be critical for the maintenance of muscle fiber size and muscle mass. Conversely, 21 gene sets were repressed by spermine oxidase and induced by immobilization and p21 (Fig. 9) ; many of these gene sets represented cellular processes that are known to be involved in muscle atrophy, including inflammation, altered protein metabolism, and extracellular matrix remodeling. Collectively, these data indicate that spermine oxidase influences skeletal muscle gene expression in a manner that helps to maintain muscle fiber size and prevent muscle fiber atrophy. These findings may also begin to explain how p21 and reduced expression of spermine oxidase trigger skeletal muscle atrophy.
DISCUSSION
In the present study, we sought to discover a previously unrecognized mechanism of muscle atrophy by identifying a skeletal muscle protein that helps to protect muscle mass but is strongly and specifically reduced by conditions that cause muscle atrophy. To this end, we performed an unbiased search, which revealed spermine oxidase, a protein not previously known to play a role in muscle atrophy.
Our data indicate that spermine oxidase is expressed at a relatively high level in healthy skeletal muscle, where it contributes to a gene expression pattern that helps to maintain muscle fiber size and prevent muscle atrophy (Fig. 10) . Our data also indicate that diverse atrophy stimuli (e.g., limb immobilization, fasting, muscle denervation, and aging) profoundly reduce spermine oxidase mRNA by upregulating skeletal muscle p21 expression. As a result, the level of spermine oxidase enzyme falls, and a new pattern of skeletal muscle gene expression emerges, leading to induction of proatrophy genes (e.g., myogenin and genes involved in inflammation and extracellular matrix remodeling) and repression of antiatrophy genes (e.g., mitofusin-2 and other genes involved in mitochondrial biogenesis and function). We speculate that this new pattern of skeletal muscle gene expression promotes atrophy of skeletal muscle fibers by impairing mitochondrial function, by stimulating inflammatory/stress signaling pathways, and perhaps by influencing other cellular processes that help to control muscle mass but have not yet been studied in the context of muscle atrophy.
In addition to identifying spermine oxidase as an important regulator of muscle gene expression and fiber size, the current study elucidates p21-mediated repression of spermine oxidase as a key mechanism of muscle atrophy. During muscle atrophy, p21 expression is upregulated by the transcription factors p53 and ATF4 (15, 17) and possibly other factors (Fig. 10) . Increased expression of p21 is necessary and sufficient for muscle fiber atrophy (17) , but the mechanism by which p21 causes muscle fiber atrophy was unknown. Our data indicate that p21 causes muscle atrophy, at least in part, by reducing spermine oxidase mRNA. Further studies will be needed to determine whether p21 reduces spermine oxidase mRNA by decreasing its transcription or by increasing its turnover, and whether p21 exerts these effects via a direct or indirect mechanism.
Understanding how spermine oxidase influences muscle gene expression is another important area for future investigation. Because spermine oxidase catalyzes the conversion of spermine to spermidine, H 2 O 2 , and 3-aminopropanal, we speculate that spermine oxidase may regulate muscle gene expression by directly altering the levels of one or more of these metabolites. In support of this idea, many studies have shown that polyamines such as spermine and spermidine can influence cellular gene expression in a variety of ways (reviewed in Ref. 37) . Our data indicate that a reduction in spermine oxidase expression (as occurs during muscle atrophy) is associated with a relative increase in the level of spermine, and not necessarily with a change in the level of spermidine. It also seems possible that muscle gene expression might be sensitive to changes in the levels of H 2 O 2 and/or 3-aminopropanal, which would be predicted to increase with spermine oxidase activity. H 2 O 2 has been shown to influence gene expression (38) , but the level of H 2 O 2 in muscle is affected by many factors. We do not yet know the relative contribution of spermine oxidase activity to skeletal muscle H 2 O 2 . To our knowledge, potential effects of 3-aminopropanal on muscle gene expression have not been investigated. Further studies will be required to investigate these issues, and to test the alternative possibilities that 1) spermine oxidase may regulate muscle gene expression by a mechanism that is independent of its known enzymatic activity, and 2) spermine oxidase may help to maintain muscle fiber size by mechanisms, direct or indirect, that are independent of changes in muscle gene expression.
Other outstanding issues are whether atrophy-associated changes in p21 and spermine oxidase expression occur in muscle fibers, satellite cells, and/or other cell types residing in skeletal muscle and whether these cell types are sensitive to changes in spermine oxidase activity. In addition, we do not yet know whether spermine oxidase expression is restricted to specific fiber types or if specific fiber types are more responsive than others to spermine oxidase. These are all important areas for future investigation.
The current data indicate that reduced spermine oxidase expression may contribute to muscle atrophy during a variety of stress conditions, including immobilization, denervation, fasting, and aging. Similarly, skeletal muscle p21 expression increases in all of these conditions, suggesting that repression of spermine oxidase, mediated by p21, may be a fundamentally conserved mechanism of skeletal muscle atrophy. Additional work will be required to understand how the p21-spermine oxidase axis connects to other key muscle atrophy pathways, such as those mediated by MuRF1, myostatin, FoxO, TWEAK, and Gadd45a (5, 6, 14, 28, 36, 41) .
Interestingly, we found that forced expression of spermine oxidase stimulated muscle fiber hypertrophy under basal conditions. On the basis of this finding, we speculate that spermine oxidase may also contribute to skeletal muscle hypertrophy. In support of this idea, previous studies have shown that at least some small molecules that reduce muscle atrophy and stimulate muscle hypertrophy (androgens and ursolic acid) strongly upregulate spermine oxidase mRNA in skeletal muscle (24, 45) . Furthermore, the androgen receptor is required to maintain normal spermine oxidase expression in skeletal muscle, as well as skeletal muscle mass (31) . It is also interesting to note that changes in polyamine levels have been associated with hypertrophy of cardiac myocytes (2, 3, 29, 43) .
In summary, the present study identifies spermine oxidase as an important positive regulator of muscle fiber size whose expression is strongly downregulated by conditions that cause muscle atrophy. This reduction in spermine oxidase enables the atrophy process and represents a potential target for therapeutic intervention.
